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Supra-treatment threshold neonatal jaundice: Incidence 
in HIV-exposed compared to non-exposed neonates at 
Queen Elizabeth Central Hospital in Blantyre, Malawi
Abstract
Introduction 
Jaundice is the yellowish pigmentation of  the skin, sclera, and mucous 
membranes resulting from bilirubin deposition. Children born to mothers 
with HIV are more likely to be born premature, with low birth weight, and 
to become septic—all risk factors for neonatal jaundice. Further, there 
has been a change in the prevention of  mother-to-child transmission 
(PMTCT) of  HIV guidelines from single-dose nevirapine to a six-week 
course, all of  which theoretically put HIV-exposed newborns at greater 
risk of  developing neonatal jaundice. 
Aim
We carried out a study to determine the incidence of  severe and clinical 
neonatal jaundice in HIV-exposed neonates admitted to the Chatinkha 
Nursery (CN) neonatal unit at Queen Elizabeth Central Hospital (QECH) 
in Blantyre.
Methods 
Over a period of  four weeks, the incidence among non-exposed neonates 
was also determined for comparison between the two groups of  infants. 
Clinical jaundice was defined as transcutaneous bilirubin levels greater 
than 5 mg/dL and severe jaundice as bilirubin levels above the age-specific 
treatment threshold according the QECH guidelines. Case notes of  babies 
admitted were retrieved and information on birth date, gestational age, 
birth weight, HIV status of  mother, type of  feeding, mode of  delivery, 
VDRL status of  mother, serum bilirubin, duration of  stay in CN, and 
outcome were extracted.
Results
Of  the 149 neonates who were recruited, 17 (11.4%) were HIV-exposed. 
One (5.88%) of  the 17 HIV-exposed and 19 (14.4%) of  132 HIV-
non-exposed infants developed severe jaundice requiring therapeutic 
intervention (p = 0.378). Eight (47%) of  the HIV-exposed and 107 (81%) 
of  the non-exposed neonates had clinical jaundice of  bilirubin levels 
greater than 5 mg/dL (p < 0.001).
Conclusions
The study showed a significant difference in the incidence of  clinical 
jaundice between the HIV-exposed and HIV-non-exposed neonates. 
Contrary to our hypothesis, however, the incidence was greater in HIV-
non-exposed than in HIV-exposed infants.
Introduction
Jaundice is the yellowish pigmentation of  the skin, sclera 
and mucous membranes.1 The yellow colour results from 
the accumulation of  bilirubin pigment in the skin.2 Neonatal 
jaundice or neonatal hyperbilirubinaemia refers to jaundice 
that is present at birth or appears at any time during the 
neonatal period.2 In neonates, hyperbilirubinaemia is 
detected when the serum bilirubin levels become greater 
than 5 mg/dL and is termed clinical jaundice.3 Jaundice can 
be  physiological or pathological.4
Physiological jaundice is a common problem in term and 
preterm infants during the first week after birth and is the 
result of  increased bilirubin production from the breakdown 
of  foetal red blood cells combined with transient limitations 
in the conjugation of  bilirubin by the immature neonatal 
liver.2 For most of  these infants, jaundice is mild and resolves 
without treatment. More than 50% of  normal newborn, and 
80% of  preterm infants, have some jaundice.5
A small group of  infants develop pathological jaundice. This 
may be an exaggeration of  normal physiologic processes or 
may be an indicator of  underlying disorders.6 Pathological 
jaundice usually appears in the first 24 hours or after the 
first week of  life, and the list of  differential diagnoses 
include haemorrhage, sepsis, and congenital infections, such 
as toxoplasmosis, rubella, cytomegalovirus, herpes, and 
syphilis.2
Risk factors of  neonatal jaundice include low birth 
weight, prematurity, ABO incompatibility, and sepsis.3 In 
Malawi, 10% of  neonates are born to HIV seroreactive 
mothers.9 Several studies have found very high rates of  
prematurity, low birth weight, and very low birth weight (all 
risk factors for neonatal jaundice) in the infants of  HIV-
positive mothers.8,9 In addition, other perinatal infections 
that predispose neonates to jaundice, such as hepatitis B 
and C, syphilis, toxoplasmosis, cytomegalovirus, herpes 
simplex virus, and tuberculosis exhibit high co-morbidity 
with HIV.10 Nevirapine has been known to cause hepatic 
inflammation and therefore is associated with increased 
levels of  serum bilirubin.10,11 The new prevention of  mother-
to-child transmission (PMTCT) guidelines from single-dose 
nevirapine prophylaxis to a six-week course in newborns,10 
means that, in theory, the risk of  developing clinical jaundice 
in HIV-exposed neonates is increased. 
Non-invasive techniques for bilirubin measurement  that 
correlate with serum bilirubin levels, such as with the 
use of  a transcutaneous bilirubinometer, may be used 
to screen infants, but determination of  serum bilirubin 
level is indicated in patients with elevated age-specific 
transcutaneous measurement, progressing jaundice, or risk 
for either haemolysis or sepsis.2 Severe jaundice is defined as 
clinical jaundice and serum bilirubin levels above treatment 
threshold levels for gestational age and postpartum age. If  
the bilirubin level is greater than the threshold value, the 
neonate is started on phototherapy.12 The levels of  bilirubin, 
which are determined as supra-threshold and require 
treatment, are different according to the days of  life and 
whether the neonate is healthy or preterm, as summarized 
in Table 1.12
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Table 1: Treatment thresholds for neonatal jaundice depending on day 
of life and clinical status of neonate12
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Jaundice—if  untreated or if  treatment thereof  is delayed—
can lead to significant neurological sequelae. These include 
movement disorders like athetoid cerebral palsy and dystonia, 
auditory dysfunction, auditory neuropathy (ANSD), 
oculomotor impairments (nystagmus, strabismus, impaired 
upward or downward gaze, and/or cortical visual impairment) 
and other disorders such as dental enamel hypoplasia/
dysplasia of  the deciduous teeth, gastroesophageal reflux, 
and impaired digestive function.2
While there is a correlation between the risk factors for 
neonates to become jaundiced and the risks and co-
morbidities that HIV-exposed neonates face, few studies have 
compared the incidence of  neonatal jaundice between HIV-
exposed and HIV-non-exposed neonates. The hypothesis of  
this study was that the incidence of  jaundice may be higher in 
HIV-exposed neonates than in HIV-non-exposed neonates.
Methods
Study population, sample size, and study setting
This prospective cohort study was conducted at the Gogo 
Chatinkha Nursery (CN) neonatal unit at Queen Elizabeth 
Central Hospital over a four-week period. The admission 
criteria for CN includes those neonates who are premature, 
of  low birth weight, or are exibiting any danger signs in a 
neonate, for example, dyspnoea or poor colour. The study 
population comprised neonates admitted to CN. Only 
neonates who met the inclusion criteria were included in the 
study after consent was obtained from their mothers.
The inclusion criteria were that newborn babies had to be 
free from jaundice and admitted to CN. The following were 
not eligible for the study: neonates who already had jaundice, 
neonates with significant congenital anomalies, and neonates 
of  mothers whose HIV statuses were not known.
The study participants were recruited using stratified 
sampling. Two groups of  eligible neonates whose mothers 
were HIV-positive and HIV-negative were identified. A 
random sample of  69 babies was drawn from each group. 
The calculated sample size of  138 (69 exposed and 69 non-
exposed) babies was generated using Epi info version 3.5, 
with a confidence level of  90%, power of  80%, exposed to 
non exposed-ratio of  1:1, risk ratio of  2.31, and an odds ratio 
of  3. However, we did not reach our sample size, as only 17 
HIV-exposed neonates were recruited. 149 neonates were 
recruited in order to increase the number of  HIV-exposed 
neonates in the study, as not many HIV-exposed neonates 
were admitted to CN during the data collection period. Data 
on the sampled babies were collected using self-administered 
questionnaires, which were provided to the mothers. Data 
were analysed using Epi Info 3.5 software.
Ethical considerations
Ethical approval was granted by the College of  Medicine 
Research and Ethics Committee (COMREC). Informed 
written consent was sought from the mothers of  the 
neonates. Before consent was obtained, the mothers were 
assured of  confidentiality. Study subjects were each assigned 
unique identification numbers.
Data collection  
Once the mothers consented, details of  the mother and 
baby were recorded on data collection forms. Babies had 
wrist bands on which their mothers’ names were written. 
These wristbands were checked daily before taking any 
measurements from the babies.  
Data management
Bilirubin levels were measured using a transcutaneous 
bilirubinometer, which was placed on the sternum and 
forehead of  each baby, and the highest reading was 
recorded. Axillary temperatures were also measured using 
a thermometer. If  a study subject’s level of  bilirubin was 
above the accepted treatment threshold, the investigators 
(three of  whom were fourth-year medical students at the 
time of  data collection) discussed the case with the doctor 
on duty for information about the treatment plan for the 
baby. The babies who developed jaundice were started on 
phototherapy. The measurements for temperature and 
bilirubin were taken every day for the duration of  stay of  the 
baby in CN. If  pyrexia or changes in condition  of  the study 
patients was noted by the investigators, this information was 
immediately relayed to the clinicians responsible for patient 
care. Babies who developed jaundice, as well as those who 
did not, were monitored throughout their duration of  stay 
in CN.
Data analysis
Microsoft Excel 2011 and Epi info 3.5 were used to record, 
store, and analyse the data that were collected.
Results
The total number of  admitted neonates from 11 September 
2013 to 9 October 2013 was 251. Of  the 251 neonates 
admitted to CN, 149 neonates were recruited into the 
study. The prevalence of  HIV among mothers giving birth 
at QECH was 13.8%. Sixty-one percent (91/149) of  the 
neonates recruited into the study were males. Ten mothers 
(6.3%) who gave consent had not been tested for HIV, hence 






















Table 2: Demographic characteristics of neonates born to HIV-
positive and HIV-negative mothers
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Over 75% of  neonates admitted to CN developed clinical 
jaundice (Table 3). Over half  (64%) of  the neonates with 
clinical jaundice were male, while the remainder (36.0%) 
were female. Gender was significantly associated with clinical 
jaundice (p = 0.033).
About 80% of  neonates had low birth weight. Seventy 
percent of  neonates with normal birth weight (birth weight 
≥ 2500g) developed clinical jaundice. However, birth weight 
was not significantly associated with clinical jaundice (p 
= 0.140). About half  of  the HIV-exposed neonates and 
the majority (81%) of  the HIV-non-exposed neonates 
developed clinical jaundice (Figure 1). HIV non-exposure 
was significantly associated with clinical jaundice (p < 0.001). 
Over 70% of  full-term neonates and about 80% of  preterm 
neonates developed clinical jaundice.
Fifteen of  the 17 HIV-exposed neonates were given 
nevirapine, as the mothers of  two HIV-exposed neonates 
refused nevirapine prophylaxis. Both neonates who were 
not given nevirapine developed clinical jaundice. Six (40%) 
of  the 15 neonates who were given nevirapine developed 
clinical jaundice.
The VDRL test was not performed on the majority of  the 
mothers (88%). None of  the mothers who were tested were 
VDRL-positive. Over 75% of  neonates whose mothers were 
not tested (VDRL test) developed clinical jaundice. 
Among neonates born via spontaneous vertex delivery 
(SVD), over 80% developed clinical jaundice. Over 60% of  
neonates born via caesarean section (CS) developed clinical 
jaundice. Almost all neonates (88%) born by alternative 
methods (breech or vacuum extraction) developed clinical 
jaundice. The mean bilirubin level for all neonates with and 



































Table 3: Associations between clinical jaundice and demographic 

















































Figure 3: Incidence of severe jaundice according to HIV exposure
About 10% of  the neonates developed severe jaundice 
and were put on phototherapy. Most of  the neonates who 
developed severe jaundice were HIV-non-exposed (Figure 
3). About 13% of  neonates with low birth weights and 15% 
of  neonates with normal birth weights developed severe 
jaundice. About 6% of  HIV-exposed neonates and 14% 
of  HIV-non-exposed neonates developed severe jaundice. 
Severe jaundice was not significantly associated with HIV 
exposure. About 12% of  term neonates and 15% of  preterm 
neonates developed severe jaundice. Sixteen (12.2%) of  the 
131 neonates whose mothers were not VDRL tested and 
4 (22%) of  the 18 neonates whose mothers were VDRL-
negative developed severe jaundice. Nine (11.4%) of  the 79 
neonates born via SVD, nine (16.7%) of  the 54 neonates born 
via CS and 2 (12.5%) of  the 16 born by alternative methods 
(for example, breech or vacuum extraction) developed severe 
jaundice. Most neonates developed severe jaundice on day 3.
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Discussion
Our study showed a strong negative association between the 
incidence of  clinical jaundice and HIV exposure. Contrary 
to our initial hypothesis, the incidence of  neonatal jaundice 
at CN was less in the HIV-exposed than in the HIV-non-
exposed group. There was no association between HIV 
exposure and severe jaundice.
Studies have found high rates of  prematurity, low birth 
weight, and very low birth weight in the infants of  HIV-
positive mothers.8,9 Notably, prematurity and low birth weight 
are risk factors that predispose HIV-exposed neonates to 
develop jaundice. The incidence of  neonatal jaundice at CN 
was, however, less in the HIV-exposed than in the HIV non-
exposed babies, and several explanations could be suggested 
for the results obtained.
First, it could be because of  the relatively small sample size of  
the study. There were fewer HIV-exposed neonates admitted 
to CN than we initially expected. This could be because most 
HIV-exposed neonates who were born at QECH did not 
meet the criteria to be admitted to CN. Consequently, the 
number of  HIV-exposed neonates was small and this affected 
our statistical analysis. The results cannot be generalised to 
the population.
Additionally, many of  the HIV-exposed neonates who were 
admitted to CN were of  low birth weight and premature, did 
not have other co-morbidities and were discharged within 
two days after admission. Bilirubin levels generally peaked 
on days 3 and 4 (Figure 2), but since most HIV-exposed 



































Table 4: Association between severe jaundice and demographic 


































Birth+weight 0.32 0.07&–&1.46 0.140
Caesarean+sec,on 0.34 0.07&–&1.63 0.175
Gesta,onal+age 1.27 0.29&–&5.47 0.753
Gender 2.62 1.08&–&6.37 0.033
HIV+status 0.10 0.03&–&0.35 p&<&0.001
SVD 1.19 0.24&–&5.83 0.834
VDRL+status 0.97 0.26&–&3.68 0.969
SVD&=&Spontaneous&vertex&delivery&&
VDRL&=&Venereal&Disease&Research&Laboratory&(test)
Table 5: Estimated odds ratios from the logistic regression model for 




Birth+weight 1.72 0.32'–'9.11 0.525
Caesarean+sec,on 1.37 0.25'–'7.48 0.714
Gesta,onal+age 0.52 0.10'–'2.67 0.432
Gender 2.59 0.80'–'8.42 0.114
HIV+status 0.38 0.05'–'3.22 0.378
SVD 1.14 0.20'–'6.41 0.880
VDRL+status 1.90 0.52'–'7.01 0.333
SVD'='Spontaneous'vertex'delivery''
VDRL'='Venereal'Disease'Research'Laboratory'(test)
Table 6: Estimated odds ratios from the logistic regression model for 
severe jaundice and several predictor variables
The peak and fall in bilirubin levels was similar for both 
clinical and severe jaundice (Figure 4).
Adjusting for birth weight, mode of  delivery, gestational 
age, gender and VDRL test, clinical jaundice was associated 
with HIV status (p < 0.001) (Table 5). Neonates with HIV 
exposure were 90% less likely to develop clinical jaundice 
than neonates without HIV exposure.
The odds of  clinical jaundice are 2.6 times higher among 
male neonates than among female neonates when other 
factors are controlled for. 
Controlling for birth weight, mode of  delivery, gestational 
age, gender, and VDRL status, severe jaundice was not 
associated with HIV status (p = 0.378 ) (Table 6).
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that they did not develop jaundice. However, these HIV-
exposed neonates might have developed jaundice after 
discharge and presented to health centres elsewhere. 
Furthermore, controlling for confounders using logistic 
regression, gender and maternal HIV status were negatively 
and significantly associated with clinical jaundice. This agrees 
with previous research done elsewhere, which showed that 
male gender is a known risk factor for pathological jaundice.13 
Birth weight, gestational age, and mode of  delivery were not 
significantly associated with jaundice. 
A possible hypothesis as to why HIV-exposed neonates 
were less likely to develop jaundice, at least in the initial days 
of  life, might be related to the Malawi’s current PMTCT 
protocol. The national PMTCT guidelines stipulate that 
all HIV-seroreactive pregnant and breastfeeding women 
should be started on an antiretroviral therapy regimen that 
contains efavirenz (along with tenofovir and lamivudine). 
The efavirenz may act as a foetal liver enzyme inducer, and 
this would help in the conjugation of  bilirubin, resulting in 
HIV-exposed neonates having less serum bilirubin levels 
than their HIV-non-exposed counterparts.
Limitations 
The study used a non-invasive technique (transcutaneous 
bilirubinometer) for measuring the bilirubin levels. These 
devices  are not always accurate, especially if  the neonate has 
been placed under phototherapy. Using the gold standard—
serum birubin level measurement—would have been more 
ideal.
The number of  neonates who developed jaundice could be 
higher than that found in this study because most neonates 
developed jaundice after being discharged from the ward, 
and this depended on the mothers noticing that their child 
was looking yellowish. 
Lastly, The sample size for HIV-exposed infants was not 
reached, as we recruited only 17 of  the calculated 69 neonates. 
The study period could have been increased, or the study field 
could have been extended to other health facilities in order 
to have had a larger sample size. With a larger sample size, 
our results could have, at least, approached generalisability 
on a national level.
Conclusions
This short cohort study showed that, in young neonates, 
jaundice was less common in HIV-exposed babies despite 
the use of  nevirapine. Although this is reassuring, a larger 
study with longer follow-up is needed.
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